

Multi-territory stroke preceded by pulmonary embolism with asymptomatic coronavirus disease 2019: a case report

Jakob Van Herck (10 1,2*, Hendrik Thoen (10 1,3, Christophe Delens (10 1, and Joeri Voet (10 1

Department of Cardiology, General Hospital AZ Nikolaas, Moerlandstraat 1, 9100 Sint-Niklaas, Belgium; Department of General Internal Medicine, University Hospitals KU Leuven, Leuven, Belgium; and ³Department of Cardiology, University Hospital Ghent, Ghent, Belgium

Received 4 June 2021; first decision 12 July 2021; accepted 15 November 2021; online publish-ahead-of-print 19 November 2021

Background

Non-bacterial thrombotic endocarditis is characterized by the presence of sterile vegetations on a cardiac valve. We present a case of multi-territory stroke caused by embolism of a non-bacterial thrombotic aortic valve endocarditis, leading to the diagnosis of a prostate adenocarcinoma with bone metastases.

Case summary

A 66-year-old patient was diagnosed with pulmonary embolism, first attributed to an asymptomatic coronavirus disease 2019 infection. Edoxaban was started, which was discontinued by the patient. Four weeks later, he presented with subacute vertigo and balance disorders. Magnetic resonance imaging showed a multi-territory stroke. A transoesophageal echocardiogram demonstrated a small vegetation on the aortic valve with moderate aortic insufficiency. Blood cultures remained negative. Malignancy screening showed a markedly elevated prostate-specific antigen. Prostate adenocarcinoma was confirmed on biopsy. A positron emission tomography revealed metastatic disease. A diagnosis of non-bacterial thrombotic endocarditis and paraneoplastic pulmonary embolism secondary to prostate cancer was made. Edoxaban was restarted and the patient was referred for treatment of the prostate adenocarcinoma. Follow-up after 5 months showed no evidence of aortic valve vegetations.

Discussion

Coronavirus disease 2019 in ambulatory patients may be insufficient as a predisposing factor for venous thromboembolism and these patients, especially the elderly, should undergo a screening for malignancy. Non-bacterial thrombotic endocarditis is a rare cause of multi-territory stroke. When related to cancer, the prostate can be the primary tumour.

Keywords

Stroke • Non-bacterial thrombotic endocarditis • Prostate cancer • Pulmonary embolism • COVID-19 •

ESC Curriculum 4.1 Aortic regurgitation • 4.11 Endocarditis

Learning points

- COVID-19 in ambulatory patient may be insufficient as a predisposing factor for venous thrombo-embolism.
- Non-bacterial thrombotic endocarditis is a rare cause of multi-territory stroke. When it is related to cancer, the prostate can be the primary tumour.

Handling Editor: Hatem Soliman Aboumarie Peer-reviewers: Ali Nazmi Calik; Ching-Hui Sia Compliance Editor: Daniel Tardo Supplementary Material Editor: Ross Thomson

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact iournals.permissions@oup.com

^{*} Corresponding author. Tel: +32478177994, Email: jakob.vanherck@gmail.com

2 J. Van Herck et al.

Introduction

Ischaemic stroke represents a large medical burden causing death and disability worldwide. A cardioembolic source is found in 20–30% of cases. Possible causes include, among others, atrial dysrhythmias, intracardiac shunts, and valvulopathy. We present a case of a patient with multi-territory stroke due to non-bacterial thrombotic endocarditis, preceded by a pulmonary embolism and asymptomatic coronavirus disease 2019 (COVID-19), leading to a new diagnosis of metastatic prostate adenocarcinoma.

Timeline

Relative point in time	Case course
Day -30	66-year-old male admitted with chest pain, diagnosis of subsegmental pulmonary embolism. Edoxaban is started after 5 days of enoxaparin. Coronavirus disease 2019 polymerase chain reaction is compatible with previous infection.
Day -23	At home discontinuation of edoxaban.
Day 1	Admitted with subacute balance disorders. Magnetic resonance imaging confirms multiterritory stroke. Re-initiation of edoxaban.
Day 3	A transthoracic echocardiogram shows no significant abnormalities.
Day 14	Ambulatory transoesophageal echocardiogram shows a small vegetation on the aortic valve with moderate aortic regurgitation.
Day 16	Blood cultures remain negative. Prostate specific antigen is significantly elevated (317 ng/mL).
Day 17	Prostate biopsies are taken. Histology confirms prostate carcinoma.
Day 19	Positron emission tomography shows multiple fluoro-deoxy-glucose avid osteoblastic bone lesions.
Day 31	Androgen deprivation therapy is initiated.
Day 120	Our patient is in good general condition. His gait has improved. Prostate specific antigen is 0.84 ng/mL.
Day 150	A control transthoracic echocardiogram shows no visible vegetations.

Case presentation

A 66-year-old Caucasian male with no previous medical history was hospitalized for chest and interscapular pain. Blood pressure and oxygen saturation on admission were normal. Electrocardiography showed normal sinus rhythm. D-dimers were > 10 000 ng/mL (normal < 500 ng/mL) and additional computed tomography (CT) angiography showed small, non-occlusive subsegmental pulmonary embolisms in the right lower lobe. A routine polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on a nasopharyngeal

swab on admission was positive with cycle threshold values >36, compatible with a previous infection. There were no signs of coronavirus disease 2019 (COVID-19) pneumonia on CT imaging. Besides chest pain, the patient was asymptomatic, oxygen saturations stayed >96% at room air. A duplex ultrasound revealed extensive superficial thrombosis in the veins of the left lower leg, with limited deep venous thrombosis in the lateral gastrocnemius. After 5 days of therapeutic enoxaparine, treatment with edoxaban 60 mg once daily was initiated.

Four weeks later our patient presented in the emergency department because of subacute vertigo, gait difficulties, and diplopia since 2 weeks. He admitted to have discontinued edoxaban as soon as one week after hospital discharge. Clinical findings included dysmetria on finger-to-nose testing in the right arm and a difficult tandem gait. Magnetic resonance imaging showed numerous ischaemic brain lesions in the cerebral (sub)cortical regions, corpus callosum and in the right cerebellar hemisphere, the latter matching with the right-sided ataxia (Figure 1).

Because of the multifocal pattern, an embolic source was suspected. Our patient reported to have an unintentional weight loss of around 4 kg (8.8 pounds), but there was no history of palpitations or fever. On physical examination, he appeared overweight (body mass index 28 kg/m²). No signs of peripheral embolism were found, there was no fever or cardiac murmur. The most important differential diagnoses were patent foramen ovale with paradoxical embolism, atrial fibrillation, and endocarditis. Rhythm monitoring showed sinus rhythm without episodes of supraventricular tachycardia. Atrial size, valvular function, and ventricular size and function appeared within the normal range on a transthoracic echocardiogram. Blood biochemistry showed a high alkaline phosphatase of 463 U/L (normal 45-117 U/L) and a mildly elevated C-reactive protein of 24 mg/L (normal < 3.0 mg/L). Sedimentation rate, complete blood count, electrolyte panel, creatinine, other liver tests, and protein electrophoresis were normal. Anticoagulation therapy with edoxaban 60 mg once daily was re-initiated.

A transoesophageal echocardiogram showed a small vegetation of $6.7 \, \text{mm} \times 5.2 \, \text{mm}$ on the aortic side of the right coronary cusp (Figure 2A, Video 1). There was a moderate eccentric aortic valve regurgitation with a jet in the direction of the anterior leaflet of the mitral valve (Figure 2B, Video 2). There was no patent foramen ovale or atrial septal defect. Multiple sets of blood cultures were taken but remained negative. Testing for causes of culture-negative infectious endocarditis endemic in our region (among others Coxiella burnetii and Bartonella spp.) were negative. Antiphospholipid antibodies testing turned out negative.

A screening for malignancy was performed. Computed tomography imaging of the chest had showed no suspicious lesions. Faecal occult blood test was negative. Serum prostate-specific antigen (PSA) appeared significantly elevated (317 ng/mL) (normal < 4.50 ng/mL). An induration on the right side of the prostate was noted during digital rectal examination. Histological examination of prostate biopsies confirmed a prostate adenocarcinoma. Staging with a fluoro-deoxy-glucose (FDG) positron emission tomography-CT scan revealed extensive FDG avid osteoblastic bone metastases and small retroperitoneal, inguinal, and axillary lymphadenopathies (*Figures 3* and 4). There was no significant increased uptake of FDG in the aortic valve vegetation. A diagnosis of advanced metastatic prostate carcinoma with secondary non-bacterial thrombotic aortic valve endocarditis was made. The previous pulmonary embolism was considered to be paraneoplastic.

Multi-territory stroke 3




Figure 1 Axial T2 fluid-attenuated inversion recovery magnetic resonance imaging images showing multiple hyperintense lesions in the cerebellum and the (sub)cortical regions, suggestive of recent ischaemic stroke of cardio-embolic source.




Figure 2 (A) Transoesophageal echocardiogram (mid-oesophageal aortic valve LAX view) showing a vegetation of $6.7 \, \text{mm} \times 5.2 \, \text{mm}$ on the aortic side of the right coronary cusp. (B) Demonstration of the eccentric aortic valve regurgitation with a jet in the direction of the anterior leaflet of the mitral valve. (Ao, ascending aorta; AV, aortic valve; LA, left atrium; LV, left ventricle; MV, mitral valve).

The prostate adenocarcinoma was treated with androgen deprivation therapy. After dental sanitation denosumab and calcium–vitamin D were started to prevent pathological fractures. Because of persistent balance disorders and writing difficulties, our patient was included in a neurological rehabilitation program. There was a good tumour response with a decrease of the PSA after 4 months to 0.84 ng/mL. His gait improved with gait revalidation training. A follow-up transthoracic echocardiogram 5 months after admission

for his balance disorders showed no visible vegetations of the aortic valve.

Discussion

The pulmonary embolism was first thought to be secondary to COVID-19, as it is shown that patients with COVID-19 have an increased thrombo-embolic risk. However, this relation is mostly

4 J. Van Herck et al.




Figure 3 Computed tomography scan demonstrating diffuse osteoblastic bone lesions in the vertebral column.



Figure 4 18-Fluoro-deoxy-glucose positron emission tomography demonstrating widespread fluoro-deoxy-glucose avid lesions in the proximal skeleton and small lymphadenopathies. There is no visible uptake of fluoro-deoxy-glucose in the aortic valve.

described in patients with severe disease, requiring supplemental oxygen or intensive care.³ For ambulatory COVID-19 patients, as in our case, there are only a few reports of venous thromboembolism,



Video I Transoesophageal echocardiogram video demonstrating a small vegetation on the right coronary cusp.



Video 2 Transoesphageal doppler video showing the eccentric aortic valve regurgitation with a jet in the direction of the anterior mitral valve leaflet.

and a causal relationship is not clear.^{3–5} Our patient was, besides chest pain, asymptomatic and did not develop other COVID-19 related symptoms during hospitalization. Hence, COVID-19 could insufficiently explain the observed pulmonary embolism. All patients who are considered to have venous thromboembolism without identifiable risk factors, such as the patient presented in this case, should undergo a clinically guided screening for occult cancer, especially older patients, since their higher prevalence of occult cancer. Screening includes at least clinical evaluation, laboratory analysis, chest imaging, faecal occult blood test, and gender-specific testing, including prostate-specific antigen testing in men.^{6,7}

Non-bacterial thrombotic endocarditis (NBTE), also known as marantic endocarditis, is a rare form of culture-negative endocarditis characterized by a sterile vegetation on a cardiac valve. The pathophysiology of NBTE most likely involves damage of the cardiac valve endothelium with subsequent deposition of sterile fibrin and platelets. It can be caused by hypercoagulability, autoimmunity, or cancer, the latter most frequently pancreatic and lung cancer. To our current knowledge, there have only been three cases reported of non-bacterial thrombotic endocarditis secondary to prostate cancer. 10–12

Multi-territory stroke 5

Non-bacterial thrombotic endocarditis is clinically characterized by systemic embolism, most commonly to the brain, while fever is mostly absent. Non-bacterial thrombotic endocarditis should therefore be considered as a rare cause of multi-territory ischaemic stroke. In patients with stroke with a suspected cardioembolic origin without other causes, a transoesophageal echocardiogram can be indicated, even when a transthoracic echocardiogram is within normal range. 13,14 Vegetations in NBTE are small (typically 3-10 mm), heterogeneous in shape, and can appear anywhere on the valve surface.^{8,15} Valve destruction and dysfunction are usually mild or absent. 8,15 Treatment of the primary cancer is paramount in patients with NBTE secondary to cancer. Traditionally, anticoagulation with low molecular weight heparines (LMWHs) is used to prevent further thrombo-embolism in patients with NBTE, which is mostly based on expert opinions by extrapolation of data from paraneoplastic venous thromboembolism.^{8,9} However, recent evidence showed noninferiority of edoxaban compared with LMWHs in patients with paraneoplastic thromboembolism, making it a valid alternative for our patient. 16

Conclusion

Coronavirus disease 2019 may be considered insufficient as a predisposing factor for venous thromboembolism in ambulatory patients. In patients with unprovoked pulmonary embolism, a screening for malignancy should be performed according to current guidelines. Non-bacterial thrombotic endocarditis should be considered as a rare cause of multi-territory stroke. The diagnosis is made by demonstrating a vegetation on a cardiac valve and an associated condition, such as cancer, after excluding infectious endocarditis. Prostate cancer can be the primary tumour causing non-bacterial thrombotic endocarditis.

Lead author biography



Jakob Van Herck, M.D., is a resident internal medicine physician at the University of Leuven, Belgium, under supervision of Prof. Dr. Willy Peetermans. Dr. Van Herck has a special interest in systemic and cardiovascular disease.

Supplementary material

Supplementary material is available at European Heart Journal—Case Reports online.

Slide sets: A fully edited slide set detailing these cases and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written consent for submission and publication of this case report, including images and associated text, has been obtained from the patient in line with COPE guidance.

Funding: None declared.

Conflict of interest: None declared.

References

- Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D et al. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18:439–458.
- Yang H, Nassif M, Khairy P, de Groot JR, Roos YBWEM, de Winter RJ et al. Cardiac diagnostic work-up of ischaemic stroke. Eur Heart J 2018;39: 1851–1860.
- 3. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. *Thromb Res* 2020;**192**:152–160.
- Laouan Brem F, Rasras H, Ouafi N, El Bazid, Z. Bilateral pulmonary embolism in patients recovered from asymptomatic COVID-19 infection. *Cureus* 2021;13: 3–8.
- Overstad S, Tjonnfjord E, Garabet L, Fronas S, Bergan J, Aballi S et al. Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting-A report of 4 cases. *Thromb Res* 2020;**194**:116–118.
- 6. Marin-Romero S, Jara-Palomares L. Screening for occult cancer: where are we in 2020? *Thromb Res* 2020;**191**:S12–S16.
- van Es N, Le Gal G, Otten H-M, Robin P, Piccioli A, Lecumberri R et al. Screening for occult cancer in patients with unprovoked venous thromboembolism. Ann Intern Med 2017;167:410

 –417.
- Hurrell H, Roberts-Thomson R, Prendergast BD. Non-infective endocarditis. Heart 2020:106:1023–1029.
- Patel MJ, Elzweig J. Non-bacterial thrombotic endocarditis: a rare presentation and literature review. BMJ Case Rep 2020;13:e238585.
- Khan K, Wahid K, Qureshi S. Nonbacterial thrombotic endocarditis as the initial presentation of prostate cancer - a case report. J Pak Med Assoc 2019;69: 1737–1740
- Doyoung K, Jarrar A, Nicholson C, Khan MZ, McLaughlin C. Abstracts from the 2020 Annual Meeting of the Society of General Internal Medicine. J Gen Intern Med 2020;35:403

 –404.
- Eftychiou C, Fanourgiakis P, Vryonis E, Golfinopoulou S, Samarkos M, Kranidis A et al. Factors associated with non-bacterial thrombotic endocarditis: case report and literature review. J Heart Valve Dis 2005;14:859–862.
- Marino B, Jaiswal A, Goldbarg S, Bernardini GL, Kerwin T. Impact of transesophageal echocardiography on clinical management of patients over age 50 with cryptogenic stroke and normal transthoracic echocardiogram. J Hosp Med 2016; 11:95–98
- Katsanos AH, Bhole R, Frogoudaki A, Giannopoulos S, Goyal N, Vrettou A-R et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology 2016;87:988–995.
- Liu J, Frishman WH. Nonbacterial thrombotic endocarditis: pathogenesis, diagnosis, and management. Cardiol Rev 2016;24:244–247.
- Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancerassociated venous thromboembolism. N Engl J Med 2018;378:615–624.